Emily Harrison, PhD
About Emily Harrison, PhD
Emily Harrison, PhD, is a Scientist II at Precision BioSciences, Inc., specializing in nanotechnology-mediated RNA delivery for therapeutic applications. She holds a PhD in Pharmacology and Experimental Neuroscience from the University of Nebraska Medical Center and has extensive research experience in RNA-based therapies and disease mechanisms.
Work at Precision BioSciences
Emily Harrison, PhD, serves as a Scientist II at Precision BioSciences, Inc. since 2022. In this role, she focuses on RNA-based therapies and leads research efforts related to hepatitis B virus (HBV). As the HBV Research Lead, she investigates innovative approaches for therapeutic applications. Her work includes exploring the translational potential of RNA delivery systems and their implications in treating various diseases.
Education and Expertise
Emily Harrison earned her Bachelor of Science in Biotechnology from the University of Nebraska Medical Center, studying from 2007 to 2011. She continued her education at the same institution, obtaining a Doctor of Philosophy in Pharmacology and Experimental Neuroscience from 2011 to 2016. Her academic background provides a strong foundation for her research in nanotechnology-mediated RNA delivery and the roles of non-coding RNA in disease mechanisms.
Background
Prior to her current position, Emily Harrison held various roles in academia. She worked as a Graduate Student at the University of Nebraska Medical Center from 2011 to 2016 and served as a Graduate Teaching Assistant for courses in Macromolecular Structure and Function and Molecular Cell and Gene Regulation. Additionally, she was an Undergraduate Research Assistant at the University of Nebraska at Omaha from 2007 to 2011, gaining early research experience.
Research Contributions
Emily Harrison's research contributions include significant work in nanotechnology and RNA delivery systems. During her post-doctoral training at the University of North Carolina at Chapel Hill from 2016 to 2022, she participated in the Carolina Cancer Nanotechnology Training Program. She has presented her findings at various conferences, including a poster on the preclinical efficacy and safety of ARCUS-POL nucleases for chronic hepatitis B, and presented at Hep-DART 2023 in Los Cabos, Mexico.